2020 IAS-USA Guidelines: Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

2020 IAS-USA Guidelines: Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

Registration Details

  • Preregistration: $35.00 (USD)
  • Preregistration ends: Thursday, October 29, 2020

Panelists

Constance A. Benson, MD
University of California San Diego
Susan P. Buchbinder, MD
University of California San Francisco
Carlos del Rio, MD
Emory University School of Medicine
Rajesh T. Gandhi, MD
Harvard Medical School
Jennifer F. Hoy, MBBS, FRACP
Monash University
Raphael J. Landovitz, MD
University of California Los Angeles
Jean-Michel Molina, MD
University of Paris Diderot
Michael S. Saag, MD
University of Alabama at Birmingham
Paul E. Sax, MD
Brigham and Women's Hospital
Davey M. Smith, MD
University of California San Diego
Melanie A. Thompson, MD
AIDS Research Consortium of Atlanta
Paul A. Volberding, MD
University of California San Francisco

October 29, 2020

12:30 – 5:00 PM ET

If you registered for the course before Wednesday, October 28, an email from IAS-USA Support (a no-reply Zoom address) with your personal link to access the virtual course was sent to you today at 3:00 PM ET. You will also receive a 1-hour reminder today at 11:30 AM ET (8:30 AM PT, 9:30 AM MT, 10:30 AM CT). Please check your spam folder if you did not receive an email.

If you registered after Wednesday, instructions on how to join are included in your registration confirmation message. Please be sure to click on the link provided in the email to get your personal link to access the virtual course. Registration is still open till the course end.

 

Agenda

Overview

Assessment of Needs

This course will review the newly released IAS-USA HIV Treatment and Prevention Guidelines, published on-line by JAMA on October 14, 2020. The HIV experts who served on the guidelines panel and wrote the 2020 recommendations will discuss the key changes and updates through a novel series of interactive panel sessions.

Learning Objectives

After completing this course, learners will be able to:

  • Describe the latest recommendations for managing HIV in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
  • Initiate and monitor HIV prevention intervention strategies using the latest recommendations, including the use of postexposure prophylaxis (PEP) and preexposure prophylaxis (PrEP), in individuals at risk for HIV infection
  • Describe the most current data on currently available and newly available antiretroviral drugs and approaches
  • Describe the current best understanding of the impact of COVID-19 on HIV

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

  • Have a solid, working knowledge of HIV disease management
  • Provide comprehensive or specialty care for patients with HIV infection

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Credits

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115.  This program is approved for 3.75 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

This program is approved for 3.75 hours of pharmacotherapy credit.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.   Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 3.75 contact hours (0.375 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event.  Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time.  The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN  # 0761-9999-20-341-L02-P

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS

Gilead Sciences, Inc
Merck & Co, Inc
ViiV Healthcare

SILVER SUPPORTER

Janssen Therapeutics

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.